High-Throughput Screening Under Static or Dynamic Hypoxia
静态或动态缺氧下的高通量筛选
基本信息
- 批准号:9315116
- 负责人:
- 金额:$ 21.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-13 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAirAnimal ModelAntineoplastic AgentsAreaBehaviorBiologicalBiological AssayBiological MarkersBreast Cancer PatientCancer cell lineCarbon DioxideCell Culture TechniquesCell SurvivalCell physiologyCellsChronicClinicalCulture MediaCultured CellsCustomDataDevicesDimensionsDoseGrowthHumanHuman Cell LineHumidifierHypoxiaIn VitroIncubatorsIndustry StandardInvestigationLaboratoriesLinkMalignant NeoplasmsMammalian CellMeasuresMetabolismMethodsMolecularMolecular AnalysisMonitorNew AgentsNormal tissue morphologyOxygenPartial PressurePatient-Focused OutcomesPatternPharmaceutical PreparationsPhysiologicalProcessPrognostic MarkerProtocols documentationPublic HealthReaction TimeReaderSystemTechnologyTimeTissuesTumor TissueVenousbiomarker developmentbiomarker discoverybiomarker identificationcancer initiationcancer therapycell growthclinically relevantculture platesdesigndriving forcedrug discoveryexperienceflasksgenetic signaturehigh standardhigh throughput screeningimprovedin vitro Modelin vivointerestlaboratory experimentmicrodevicenoveloncologyoxygen transportplanetary Atmosphereprognosticprotein expressionpurgeresponseresponse biomarkerscreeningtissue culturetooltumortumor microenvironmenttumor progression
项目摘要
ABSTRACT
The presence of hypoxia in a many human tumors is a widely observed negative prognostic indicator.
Laboratory experiments in animal models and in vitro systems are consistent with the clinical observations
showing that hypoxia is a major driving force in cancer progression. Since hypoxia is difficult to control and
measure in animal models, in vitro approaches offer the best opportunity for detailed molecular analysis of
the influence of oxygen on cancer initiation, progression and analysis. However, clinical tumors display a
range of oxygen levels with some regions that are chronically hypoxic whereas other regions experience time-
dependent changes, i.e. cycling hypoxia. This further complicates systematic analysis of hypoxic responses
as there are literally an infinite number of static and cycling hypoxia patterns that can be probed. To date,
studies of cycling hypoxia usually are limited to probing a single, arbitrarily chosen cycling pattern that may
not be clinically relevant. In order to facilitate screening of both chronic and dynamic changes in hypoxia, we
propose to develop a technology that can deliver a range of hypoxia levels, either static or cycling, to each
row of a standard multiwell tissue culture plate. This allows monitoring of molecular adaptation, cell growth
and drug response under a range of oxygen concentrations simultaneously. The initial studies will
demonstrate the technology on a standard 96-well plate format that is compatible with current multichannel
pipettors, plate readers and laboratory protocols that allows immediate adoption to any oncology laboratory.
The same principles can be used in any multiwell plate to aid in assessing the effect of oxygen on cell growth
and viability, tumor progression, biomarker identification and therapy response. There is no current
technology that allows these types of investigations in a standard high-throughput format. This technology
addresses at least two areas of interest in the RFA as it will aid in (i) the elucidation of the basic mechanisms
underlying cancer initiation and progression and (ii) facilitate/accelerate the processes of drug discovery.
摘要
在许多人类肿瘤中缺氧的存在是广泛观察到的负面预后指标。
动物模型和体外系统的实验室实验与临床观察一致
表明缺氧是癌症进展的主要驱动力。由于缺氧难以控制,
在动物模型中进行测量,体外方法为详细的分子分析提供了最好的机会。
氧对癌症发生、发展的影响及分析。然而,临床肿瘤显示出
氧气水平的范围与一些地区是慢性缺氧,而其他地区的经验时间-
依赖性变化,即循环缺氧。这进一步使缺氧反应的系统分析复杂化
因为实际上存在可以探测的无限数量的静态和循环缺氧模式。到目前为止,
循环缺氧的研究通常限于探测单一的、任意选择的循环模式,
与临床无关。为了便于筛查缺氧的慢性和动态变化,我们
我建议开发一种技术,可以提供一系列的缺氧水平,无论是静态或循环,每个
一排标准多孔组织培养板。这可以监测分子适应,细胞生长
和药物反应。初步研究将
在与当前多通道兼容的标准96孔板格式上演示该技术
移液器、读板器和实验室协议,允许立即采用任何肿瘤实验室。
相同的原理可用于任何多孔板,以帮助评估氧对细胞生长的影响
和生存力、肿瘤进展、生物标志物鉴定和治疗反应。没有电流
技术,允许这些类型的调查在一个标准的高通量格式。这项技术
解决了RFA中至少两个感兴趣的领域,因为它将有助于(i)阐明基本机制
潜在的癌症起始和进展,以及(ii)促进/加速药物发现的过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL GAMCSIK其他文献
MICHAEL GAMCSIK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL GAMCSIK', 18)}}的其他基金
PDAC-on-a-Chip for Selection of Aggressive, Therapy-Resistant Tumor Cells
用于选择侵袭性、治疗耐药性肿瘤细胞的 PDAC 芯片
- 批准号:
8384934 - 财政年份:2012
- 资助金额:
$ 21.44万 - 项目类别:
PDAC-on-a-Chip for Selection of Aggressive, Therapy-Resistant Tumor Cells
用于选择侵袭性、治疗耐药性肿瘤细胞的 PDAC 芯片
- 批准号:
8518272 - 财政年份:2012
- 资助金额:
$ 21.44万 - 项目类别:
Spectroscopic Imaging of Antioxidant Metabolism in the Brain
大脑中抗氧化剂代谢的光谱成像
- 批准号:
7236870 - 财政年份:2007
- 资助金额:
$ 21.44万 - 项目类别:
Spectroscopic Imaging of Antioxidant Metabolism in the Brain
大脑中抗氧化剂代谢的光谱成像
- 批准号:
7489932 - 财政年份:2007
- 资助金额:
$ 21.44万 - 项目类别:
Noninvasive Monitoring Glutathione Metabolism in Tumors
无创监测肿瘤中的谷胱甘肽代谢
- 批准号:
7342396 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Noninvasive Monitoring Glutathione Metabolism in Tumors
无创监测肿瘤中的谷胱甘肽代谢
- 批准号:
7209039 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Noninvasive Monitoring Glutathione Metabolism in Tumors
无创监测肿瘤中的谷胱甘肽代谢
- 批准号:
7760978 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
Noninvasive Monitoring Glutathione Metabolism in Tumors
无创监测肿瘤中的谷胱甘肽代谢
- 批准号:
7578281 - 财政年份:2006
- 资助金额:
$ 21.44万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.44万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 21.44万 - 项目类别:
Standard Grant














{{item.name}}会员




